The purpose of the study is three-fold. The primary aim is to identify the proportion of
Long-Haul COVID (LHC) and non-LHC volunteers with relevant symptoms actually have postural
orthostatic tachycardia syndrome (POTS). The second is to determine benefit of ivabradine
treatment. Ivabradine is a drug approved to treat tachycardia in persons with heart failure.
The third is to characterize risk factors and outcomes among volunteers with and without LHC.
This will include comparison with COVID-19-positive individuals who did not develop
long-COVID symptoms.
The study will improve basic and applied knowledge of LHC and its associated cardiovascular
and autonomic consequences. Cellular and molecular characterization of LHC and non-LHC
participants will be performed with a nested clinical trial for Ivabradine responsiveness on
reduction of tachycardia. It is hoped that a greater understanding of LHC, and related
autonomic dysfunction in particular will help to identify treatment paradigms and therapeutic
targets for improving recovery and enhancing health for those affected.
Phase:
Phase 4
Details
Lead Sponsor:
Uniformed Services University of the Health Sciences